Another multicenter retrospective study from Japan (53) revealed that probiotics administration was relevant to the survival and disease control in advanced or recurrent NSCLC patients that undergone anti-PD-1 monotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.